for the NovoLog Mix-vs-Exenatide Study Group. Eﬃ   cacy and  safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009; 25: 65–75.  20 Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C,  Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009; 11: 1153–62. 21 Inagaki N, Atsumi Y , Oura T, Saito H, Imaoka T. Eﬃ   cacy and  safety proﬁ  le of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther 2012; 34: 1892–908.e1.